ReShape Lifesciences shares are trading higher after the company announced it signed an exclusive license agreement with Biorad Medisys for Obalon Gastric Balloon System.
Portfolio Pulse from Benzinga Newsdesk
ReShape Lifesciences has signed an exclusive license agreement with Biorad Medisys for the Obalon Gastric Balloon System, causing its shares to trade higher.
September 21, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ReShape Lifesciences' stock is trading higher following the announcement of an exclusive license agreement with Biorad Medisys.
The exclusive license agreement with Biorad Medisys for the Obalon Gastric Balloon System is a positive development for ReShape Lifesciences. This partnership could potentially lead to increased revenues and profitability for the company, which is likely why the stock is trading higher.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100